Design and cellular kinetics of dansyl-labeled CADA derivatives with anti-HIV and CD4 receptor down-modulating activity

Biochemical Pharmacology

Volumn 74, Issue 4, 2007, Pages 566-578

  Vermeire, Kurt ^a   Lisco, Andrea ^b   Grivel, Jean Charles ^b   Scarbrough, Emily ^c   Dey, Kaka ^c   Duffy, Noah ^c   Margolis, Leonid ^b   Bell, Thomas W ^c   Schols, Dominique ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c UNIVERSITY OF NEVADA   (United States)

Author keywords

Anti HIV; CADA; CD4 receptor; Cellular kinetics; Dansyl; Reversible Down modulation

Indexed keywords

CD4 RECEPTOR; CELL SURFACE RECEPTOR; CYCLOTRIAZADISULFONAMIDE; DANSYL CHLORIDE; ES KKD 024; KKD 014; KKD 015; KKD 016; SULFONAMIDE; TNX 355; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG UPTAKE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

ANTI-HIV AGENTS; ANTIGENS, CD4; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DANSYL COMPOUNDS; DIMETHYL SULFOXIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG DESIGN; FLOW CYTOMETRY; HETEROCYCLIC COMPOUNDS; HIV-1; HUMANS; IMMUNOHISTOCHEMISTRY; KINETICS; MOLECULAR STRUCTURE; POLOXAMER; SOLVENTS; SPECTROMETRY, FLUORESCENCE; SULFONAMIDES; SURFACE-ACTIVE AGENTS; TRANSFECTION;

EID: 34447288211     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.05.018     Document Type: Article

References (30)

1. Dalgleish A.G., Beverley P.C., Clapham P.R., Crawford D.H., Greaves M.F., and Weiss R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312 (1984) 763-767
2. Klatzmann D., Champagne E., Chamaret S., Gruest J., Guetard D., Hercend T., et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312 (1984) 767-768
3. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., et al. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272 (1996) 1955-1958
4. Feng Y., Broder C.C., Kennedy P.E., and Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272 (1996) 872-877
5. Berger E.A., Doms R.W., Fenyo E.M., Korber B.T., Littman D.R., Moore J.P., et al. A new classification for HIV-1. Nature 391 (1998) 240
6. Kuritzkes D.R., Jacobson J., Powderly W.G., Godofsky E., DeJesus E., Haas F., et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 189 (2004) 286-291
7. Vermeire K., and Schols D. Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor. Expert Opin Investig Drugs 14 (2005) 1199-1212
8. Platt E.J., Madani N., Kozak S.L., and Kabat D. Infectious properties of human immunodeficiency virus type 1 mutants with distinct affinities for the CD4 receptor. J Virol 71 (1997) 883-890
9. Kabat D., Kozak S.L., Wehrly K., and Chesebro B. Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol 68 (1994) 2570-2577
10. Moore J.P., and Doms R.W. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci USA 100 (2003) 10598-10602
11. Vermeire K., Zhang Y., Princen K., Hatse S., Samala M.F., Dey K., et al. CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virology 302 (2002) 342-353
12. Vermeire K., Princen K., Hatse S., De Clercq E., Dey K., Bell T.W., et al. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS 18 (2004) 2115-2125
13. Vermeire K., and Schols D. Specific CD4 down-modulating compounds with potent anti-HIV activity. J Leukoc Biol 74 (2003) 667-675
14. Lisco A., Grivel J.C., Biancotto A., Vanpouille C., Origgi F., Malnati M.S., et al. Viral interactions in human lymphoid tissue: human herpesvirus 7 suppresses the replication of CCR5-tropic human immunodeficiency virus type 1 via CD4 modulation. J Virol 81 (2007) 708-717
15. Lipkowski A.W., Misicka A., Kosson D., Kosson P., Lachwa-From M., Brodzik-Bienkowska A., et al. Biological properties of a new fluorescent biphalin fragment analogue. Life Sci 70 (2002) 893-897
16. Schiller P.W. Study of adrenocorticotropic hormone conformation by evaluation of intramolecular resonance energy transfer in N-dansyllysine 21-ACTH-(1-24)-tetrakosipeptide. Proc Natl Acad Sci USA 69 (1972) 975-979
17. Bartzatt R. Dansylation of hydroxyl and carboxylic acid functional groups. J Biochem Biophys Methods 47 (2001) 189-195
18. Bell T.W., Anugu S., Bailey P., Catalano V.J., Dey K., Drew M.G., et al. Synthesis and structure-activity relationship studies of CD4 down-modulating cyclotriazadisulfonamide (CADA) analogues. J Med Chem 49 (2006) 1291-1312
19. Vermeire K., Bell T.W., Choi H.J., Jin Q., Samala M.F., Sodoma A., et al. The anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor. Mol Pharm 63 (2003) 203-210
20. Owen C.S. Phorbol ester (12-O-tetradecanoylphorbol 13-acetate) partially inhibits rapid intracellular free calcium transients triggered by anti-immunoglobulin in murine lymphocytes. J Biol Chem 263 (1988) 2732-2737
21. 2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometry. Cytometry 51A (2003) 35-45
22. Turcatti G., Zoffmann S., Lowe III J.A., Drozda S.E., Chassaing G., Schwartz T.W., et al. Characterization of non-peptide antagonist and peptide agonist binding sites of the NK1 receptor with fluorescent ligands. J Biol Chem 272 (1997) 21167-21175
23. Turner J.H., and Raymond J.R. Interaction of calmodulin with the serotonin 5-hydroxytryptamine2A receptor. A putative regulator of G protein coupling and receptor phosphorylation by protein kinase C. J Biol Chem 280 (2005) 30741-30750
24. Berque-Bestel I., Soulier J.L., Giner M., Rivail L., Langlois M., and Sicsic S. Synthesis and characterization of the first fluorescent antagonists for human 5-HT4 receptors. J Med Chem 46 (2003) 2606-2620
25. Chao J., Seiler N., Renault J., Kashiwagi K., Masuko T., Igarashi K., et al. N1-dansyl-spermine and N1-(n-octanesulfonyl)-spermine, novel glutamate receptor antagonists: block and permeation of N-methyl-d-aspartate receptors. Mol Pharm 51 (1997) 861-871
26. Berlot J.P., Lutz T., Cherkaoui M.M., Nicolas-Frances V., Jannin B., and Latruffe N. Properties of a fluorescent bezafibrate derivative (DNS-X). A new tool to study peroxisome proliferation and fatty acid beta-oxidation. Lipids 35 (2000) 1397-1404
27. Sharova N., Swingler C., Sharkey M., and Stevenson M. Macrophages archive HIV-1 virions for dissemination in trans. EMBO J 24 (2005) 2481-2489
28. Turville S.G., Vermeire K., Balzarini J., and Schols D. Sugar-binding proteins potently inhibit dendritic cell human immunodeficiency virus type 1 (HIV-1) infection and dendritic-cell-directed HIV-1 transfer. J Virol 79 (2005) 13519-13527
29. Cameron P.U., Handley A.J., Baylis D.C., Solomon A.E., Bernard N., Purcell D.F., et al. Preferential infection of DC during HIV-1 infection of blood leukocytes. J Virol 81 (2007) 2297-2306
30. Shattock R., and Solomon S. Microbicides-aids to safer sex. Lancet 363 (2004) 1002-1003